Speciality Medicines IPO Details
Speciality Medicines IPO Summary
Speciality Medicines IPO DRHP (Draft Red Herring Prospectus) has been Exchange Approval Received.
Pre-issue shareholding stands at 64,35,796, which will increase to 87,35,796 post-issue.
Speciality Medicines IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.
The Lead Managers for Speciality Medicines IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Ekadrisht Capital Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Speciality Medicines Limited DRHP.
Speciality Medicines IPO Details
Speciality Medicines IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| To be announced | |||
Speciality Medicines IPO Reservation
Promoter Holding
Documents
Speciality Medicines IPO Valuations
Speciality Medicines Financial Information
| Period Ended | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 26.44 | 23.43 | 13.26 | 5.78 |
| Total Income | 8.37 | 27.66 | 23.26 | 40.45 |
| Profit After Tax | 2.3 | 4.55 | 1.69 | 1.48 |
| Net Worth | 19.23 | 16.61 | 5.87 | 1.93 |
| Reserves and Surplus | 14.08 | 11.5 | 2.05 | 1.72 |
| Total Borrowing | 2.53 | 2.86 | 3.64 | 1.18 |
| Amount in ₹ Crore | ||||
About Speciality Medicines IPO
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat complex chronic conditions — across both domestic and international markets.
The company’s portfolio includes a wide range of speciality pharmaceutical finished formulations such as capsules, creams, eye drops, gels, infusions, inhalations and inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, oral suspensions, sachets, suspensions, and tablets.
Through wide-ranging distribution channels, the company has built a trusted reputation with clients across more than 20 states in India and over 35 countries worldwide.
Speciality Medicines Limited offers over 650 products (as of July 31, 2024) under the unregistered category, with a particular focus on therapeutic areas like:
- Oncology
- Immunology
- Neurology
- Rare Diseases
Additionally, the company’s product range includes human and animal medicines, vaccines, and plasma products — all sourced from manufacturers that comply with global quality standards like EUGMP and PICS.
Global Expansion and Registrations
As of July 31, 2024, Speciality Medicines Limited has:
- 1 plasma product registered in Bolivia
- 127 products under registration across 8 countries
As of July 31, 2024, Speciality Medicines Limited employs a team of 20 permanent employees across various departments, contributing to the company’s smooth and efficient operations.
Strength Of Speciality Medicines IPO
Risk Of Speciality Medicines IPO
Objectives Speciality Medicines IPO
To be announced
Company Contact Details
Speciality Medicines Ltd.
913, One World West, S. No. 396, FP 119,
Village- Vejalpur, Ahmadabad City,
Ahmedabad, Gujarat, India,
Ahmedabad, Gujarat, 380051
Phone: +91 22 4604 5344
Email: investors.grievances@specialitymedicine.com
Website: http://www.specialitymedicine.com/
Registrar Contact Details
Market Maker
Speciality Medicines FAQs
The Speciality Medicines IPO is a SME public issue comprising 0 equity shares with a face value of ₹10 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
Skyline Financial Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the BSE
As of now, the current GMP stands at TBA.
Quick Links
Comments
